Wang Yichun, Wang Fan
Department of Radiation Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, People's Republic of China.
Cancer Manag Res. 2020 Dec 18;12:13023-13032. doi: 10.2147/CMAR.S286074. eCollection 2020.
Multidisciplinary therapies can improve the survival of patients with locally advanced esophageal carcinoma. However, the determination of the optimal modality is still a controversial subject. Many randomized controlled trials in the late 20th century showed that there was no survival benefit when postoperative radiotherapy was added to surgery for esophageal carcinoma. As a result, the treatment modality shifted thereafter to neoadjuvant therapies. Even so, these trials are criticized for many limitations and an increasing number of studies (mainly nonrandomized controlled trials) has indicated that postoperative radiotherapy/chemoradiotherapy can improve the survival of patients with a poor prognosis after R0 esophagectomy. Additionally, a large number of patients with locally advanced esophageal carcinoma still choose upfront surgery in the clinical practice due to many reasons. Therefore, postoperative radiotherapy seems to be a feasible treatment for these patients with a poor prognosis, particularly in the new era of conformal radiotherapy. Here, we review published studies on postoperative radiotherapy/chemoradiotherapy, and we discuss the clinical issues related to postoperative radiotherapy, such as the indication, target volume, total radiation dosage, time interval and complications of postoperative radiotherapy with or without chemotherapy, to make recommendations of postoperative radiotherapy for both current practice and future research in esophageal carcinoma.
多学科治疗可提高局部晚期食管癌患者的生存率。然而,确定最佳治疗方式仍是一个有争议的话题。20世纪后期的许多随机对照试验表明,食管癌手术后加用术后放疗并无生存获益。因此,此后治疗方式转向新辅助治疗。即便如此,这些试验因诸多局限性而受到批评,越来越多的研究(主要是非随机对照试验)表明,R0食管切除术后,术后放疗/放化疗可提高预后较差患者的生存率。此外,由于多种原因,大量局部晚期食管癌患者在临床实践中仍选择直接手术。因此,术后放疗似乎是这些预后较差患者的一种可行治疗方法,尤其是在适形放疗的新时代。在此,我们回顾已发表的关于术后放疗/放化疗的研究,并讨论与术后放疗相关的临床问题,如术后放疗(无论是否联合化疗)的适应证、靶区体积、总放射剂量、时间间隔和并发症,以便为食管癌当前的临床实践和未来研究提供术后放疗的建议。